Overview: Pompe Disease Quantitative TestIntroduction: The Pompe Disease Quantitative Test measures GAA enzyme activity to diagnose Pompe disease, causing muscle weakness. Aligned with 2023 ACMG guidelines, it uses PCR for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Pompe disease.
Other Names: Pompe Disease Assay, GAA Enzyme Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Pompe disease testing began in the 1990s with enzyme replacement therapy research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures GAA enzyme activity to diagnose Pompe disease, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. GAA Enzyme Activity
Pretest Condition: No fasting required. Collect whole blood or fibroblasts. Report history of muscle weakness or metabolic symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Fibroblasts (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, respiratory issues, or family history of Pompe disease. Include current medications, especially enzyme replacement therapy.
Consent: Written consent required, detailing the tests purpose, Pompe disease implications, and risks of sample collection.
Procedural Considerations: Uses fluorometric or PCR-based assays to measure GAA enzyme activity. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Pompe disease diagnosis.
Factors Affecting Result Accuracy: Low enzyme yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Reduced GAA activity confirms Pompe disease, guiding enzyme replacement therapy. Normal activity may require genetic testing.
Specialist Consultation: Consult a geneticist or neurologist for result interpretation and treatment planning.
Additional Supporting Tests: GAA gene sequencing, muscle biopsy, or electromyography to confirm Pompe disease diagnosis.
Test Limitations: Non-specific for certain metabolic disorders; clinical correlation is needed. Sample quality affects sensitivity.
References: ACMG Pompe Disease Guidelines, 2023; American Journal of Medical Genetics, Hirschhorn R, 2022.
